A therapy jointly developed by Switzerland’s Roche Holding AG and Cambridge, Mass.-based Blueprint Medicines Corp. was approved by the U.S. health regulator for the treatment of patients with a type of non-small cell lung cancer (NSCLC).
FDA Approves Eli Lilly’s Precision Oncology Treatment for Certain Lung and Thyroid Cancers
Accelerated Approval, Approvals, FDA, FDA/Regulatory, Metastatic Rearranged During Transfection (RET) Fusion-Positive Non-Small Cell Lung Cancer (NSCLC), New Drug Approvals, Precision Oncology, Product Launches, RET Kinase Inhibitors, Safety Warnings, Specialty Pharmacies, TumorsEli Lilly is moving quickly to get the newly approved precision oncology treatment Retevmo for certain lung and thyroid cancers into the hands of patients.